CTOs on the Move

JeNu Biosciences

www.jenu.com

 
JeNu Biosciences was founded by a leading Washington bio scientist and a medical technology entrepreneur. While working on an ultrasound device for topical drug delivery, they became curious about using ultrasound to improve cosmetic skin care product delivery. High energy ultrasound has been proven effective at pushing drugs through the skin, but in the process cells are damaged and high heat causes intense pain. But since cosmetics only need to be absorbed into the top layer of skin rather than through the skin like drugs they thought a low energy ultrasound device might work. After many attempts they proved that ...
  • Number of Employees: 0-25
  • Annual Revenue: $0-1 Million
  • www.jenu.com
  • 1101 N Northlake Way Ste 200
    Seattle, WA USA 98103
  • Phone: 866.565.5368

Executives

Name Title Contact Details

Similar Companies

Mount St Joseph

Mount St Joseph is a Waterville, ME-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Sidney Regional Medical Center

Sidney Regional Medical Center (SRMC) is a 25-bed, non-profit CAH designated healthcare facility. SRMC is committed to providing high-quality compassionate care by offering a wide array of services and surgeries. SRMC has been a part of the community since 1955.

Melaleuca

Welcome to the largest online wellness shopping club. Our mission is to enhance the lives of those we touch by helping people reach their goals.

Shawnee Mission Medical Center

Shawnee Mission Medical Center is one of the leading companies in Healthcare, Pharmaceuticals, and Biotech industry. Shawnee Mission Medical Center is based in Overland Park, KS. You can find more information on Shawnee Mission Medical Center at www.shawneemission.org

Telesta Therapeutics

Telesta Therapeutics is a biopharmaceutical company focused on the development, manufacturing and commercialization of transformative human therapeutics. Our main focus is on novel medicines that address major unmet medical needs, particularly in oncology. Our anchor product, MCNA, has completed a Phase III pivotal study in patients with non-muscle invasive bladder cancer that have failed the first line therapy, bacillus Calmette-Guérin (BCG). Telesta submitted a Biologics Licensing Application (BLA) for MCNA with the U.S. FDA on June 29, 2015 and is seeking, upon marketing approval in the U.S., to make MCNA available for patients and their physicians. Our ultimate goal is to transform the treatment landscape and prolong and improve the lives of those affected by bladder cancer, one of the most common types of cancers today.